The 3rd annual meeting in Atlanta gives dermatology NPs and PAs 4 case-based breakout sessions and a general education session in a focused, small-group setting.
News|Articles|June 2, 2025
Dermatology Conferences and Meetings Calendar: June 2025
Author(s)Emma Andrus, Editor
Listen
0:00 / 0:00
Key Takeaways
- A list of dermatological meetings for June 2025 has been compiled from reader responses.
- Dermatology professionals have shared their anticipated conferences and meetings for the year.
Dermatology Times has compiled a list of dermatological meetings taking place during the month of June.
Advertisement
Dermatology Times has asked our readers to share with us what conferences and meetings they are looking forward to or planning to attend in 2025.
Using these responses, we have compiled a list of dermatological meetings taking place in June.
Interested in sharing what conferences you are interested in or planning to attend this year? Email our team at
June
Rome, Italy
June 6-7, 2025: Revolutionizing Atopic Dermatitis
Nashville, Tennessee
June 18-21, 2025: Maui Derm NP+PA Summer
Colorado Springs, Colorado
June 18-21, 2025: XIV International Congress of Dermatology
Rome, Italy
Washington, DC
Advertisement
Related to this article
SPD 2026 highlighted advances in pediatric dermatology spanning textured hair care, vitiligo, vascular anomalies, mental health, genetics, and collaborative care.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
Advertisement
Advertisement